Melbourne Blood Specialists Logo

Our research

Our doctors believe that participating in research is the best way to ensure that our patients receive the best care and gain access to the latest treatment for their condition. Our doctors attend and present at conferences in Europe and USA several times every year. We list a selection of articles published by our doctors in international journals over the past three years:

  • Effective Treatment of Waldenstrom’s Macroglobulinaemia Associated Pure Red Cell Aplasia with Standard Antilymphomatous Chemotherapy. Leukemia & Lymphoma, in press.
  • High Risk Diffuse Large B-Cell Lymphoma – Can We Do Better than R-CHOP? Leukemia & Lymphoma 2013, in press.
  • Price of Drugs for Chronic Myeloid Leukemia (CML): Reflection of the Unsustainable Cancer Drug Prices – Perspective of CML Experts. Blood 2013, in press.
  • A Phase 2, Multicentre, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects with Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma: the EXPECT Trial. Lancet Oncology 2013, in press.
  • Perioperative Management of Anticoagulation in Elective Surgery. Australia and New Zealand Journal of Surgery 2013, In press.
  • CD38 Expression in CLL – A Dynamic Marker of Prognosis. Leukemia & Lymphoma, 2013, in press.
  • Radiotherapy in Orbital Lymphoma: Optimizing the Backbone to Build Upon. Leukemia & Lymphoma, 2013;54:445-6.
  • Delayed Targeting of CD39 to Activated Platelet GPIIb/IIIa via a Single-Chain Antibody: Breaking the Link Between Antithrombotic Potency and Bleeding? Blood 2013, prepublished Feb 4.
  • Protein Kinase C Isoform Expression in Chronic Lymphocytic Leukemia: Potential Target for Therapy? Leukemia & Lymphoma 2013, in press.
  • Rituximab is Associated with Improved Survival for Aggressive B-Cell Central Nervous System Lymphoma. Neuro-Oncology 2013, in press.
  • Investigational Janus Kinase Inhibitors. Expert Opinion on Investigational Drugs 2013, prepublished Feb 23, 2013.
  • Allogeneic Immunity and Anti-CD20 Therapy: A Potent Combination in the Treatment of a Patient with Richter Transformation of CLL. Leukemia & Lymphoma 2013; 54:7-8.
  • Selection of Rituximab Dosage in Chronic Lymphocytic Leukemia : Where is the Evidence? Leukemia & Lymphoma, prepublished Sep 28, 2012.
  • Darbepoietin-α has Comparable Erythropoietic Stimulatory Effects to Recombinant Erythropoietin whilst Preserving the Bone Marrow Microenvironment. Haematologica 2012, prepublished Dec 14.
  • Chronic Lymphocytic Leukemia Presenting as an Intracranial Epidural Mass in a Patient with Myeloproliferative Neoplasm Associated with JAK2 V617F Mutation. Leukemia & Lymphoma, prepublished Nov 19, 2012.
  • Out of Sight, Out of Mind: An Audit of Inferior Vena Cava Filter Insertion and Clinical Follow-up in an Australian Institution and Literature Review. Internal Medicine Journal, prepublished July 4, 2012.
  • Serum Protein Electrophoresis: A Precautionary Tale. Pathology 2012, 44:371-3.
  • CGH and SNP Array using DNA Extracted from Fixed Cytogenetic Preparations and Long-Term Refrigerated Bone Marrow Specimens. Mol Cytogenet 2012, Feb 2.
  • Successful Use of Eltrombopag without Splenectomy in Refractory HIV-Related Immune Reconstitution Thrombocytopenia. AIDS. 2012 Sep 24;26(15):1977-9.
  • Phosphatidylinositol-3 kinase Activity in B cells is Negatively Regulated by Lyn Tyrosine Kinase. Immunol Cell Biol 2012, 90:903-11.
  • Lenalidomide in Multiple Myeloma: Current Status and Future Potential. Am J Hematol, 2012; 87:1089-95.
  • Diagnostic Techniques and Therapeutic Challenges in Patients with TP53 Dysfunctional Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 2012; 53:2105-15.
  • A Case of ALK-Negative Anaplastic Large Cell Lymphoma Associated with Hypereosinophilia, Granulomatous Myositis and Vasculitis. Leukemia & Lymphoma 2012; 53:2279-82.
  • Peripheral T-cell and NK/T-cell Lymphomas: A Clinicopathological Study from One Australian Center. Histopathology 2012; 61: 212-23.
  • Predicting Survival in Chronic Lymphocytic Leukemia. Expert Review of Anticancer Therapy 2012; 12:393-403.
  • Modifying the Immune System to Treat Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 2012; 53:177-178.
  • Fludarabine, Cyclophosphamide and Rituximab (FCR) Chemotherapy Followed by Rituximab Maintenance in Follicular Lymphoma: High Efficacy May Come at a Cost? Leukemia & Lymphoma 2011; 52:729-731.
  • Thromboprophylaxis Use in Medical and Surgical Inpatients and the Impact of an Electronic Risk Assessment Tool as part of a Multi-factorial Intervention. A Report on Behalf of the elVis Study Investigators. J Thromb Thrombolysis 2011;32:279.
  • A High Rate of Durable Responses with Romidepsin, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Blood 2011; 118:6274-83.
  • Use of Empiric Antimicrobial Therapy in Neutropenic Fever. Internal Medicine Journal 2011; 41:90-101.
  • The Symptom Burden of Patients with Hematological Malignancy: a Cross-Sectional Observational Study. J Pain Symptom Manage. 2011;42(3):432-42.
  • Neutropenia and Anemia with Reduced Serum Vitamin B(12) [comment]. American Journal of Hematology 2011 Oct 20.
  • A Precautionary Tale. Pathology 2011. 44(4):731
  • Evidence of Platelet Activation at Medically Used Hypothermia and Mechanistic Data Indicating ADP as a Key Mediator and Therapeutic Target. Arterioscler Thromb Vasc Biol. 2011;31:1607-16
  • Managing Multiple Myeloma in the Elderly: Are We Making Progress? Expert Review of Hematology 2011;4:301-15.
  • Reversal of Transfusion Dependence by Tumor Necrosis Factor Inhibitor Treatment in a Patient with Concurrent Rheumatoid Arthritis and Primary Myelofibrosis. J Clin Rheumatol 2011; 17:211-3.
  • Failure of Eculizumab to Correct Paroxysmal Cold Hemoglobinuria. Ann Hematol 2011; 90:989.
  • The Immunostimulatory Effect of Lenalidomide on NK-cell Function is Profoundly Inhibited by Concurrent Dexamethasone Therapy. Blood 2011;117:1605-13.
  • Drug-Mediated and Cellular Immunotherapy in Multiple Myeloma. Immunotherapy 2010;2:243-55.
  • Fludarabine Based Combinations are Highly Effective as First-Line or Salvage Treatment in Patients with Waldenstrom Macroglobulinemia. Leukemia & Lymphoma 2010; 51:2188-2197.
  • Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Following Fludarabine Combination Chemotherapy. Leukemia 2010, 24:2056-2062.
  • The Myotubularin Phosphatase MTMR4 Regulates Sorting from Early Endosomes. J Cell Sci. 2010;123(Pt 18):3071-83
  • Hepatitis B Reactivation And Rituximab-Containing Chemotherapy – An Increasingly Complex Clinical Challenge. Leukemia & Lymphoma 2010; 51:1592.
  • Immunohistochemical Detection of ZAP-70 In Chronic Lymphocytic Leukemia Predicts Immunoglobulin Heavy Chain Gene Mutation Status And Time To Progression. Modern Pathology 2010; 23:1518-23.
  • New Angles of Attack in the Fight Against Chronic Lymphocytic Leukemia: The Advent of Novel Non-Chemotherapeutic Agents. Leukemia & Lymphoma 2010; 51:1596.
  • The Efficacy and Stem Cell Toxicity of Cladribine and Rituximab in the Treatment of Patients with Chronic Lymphocytic Leukemia: Are All Purine Analogues Created Equal?. Leukemia & Lymphoma 2010; 51: 571-3.
  • New Agents for the Treatment of Genetically High Risk Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 2010; 51:3-4.
  • Chemoimmunotherapy of Chronic Lymphocytic Leukemia. Nature Reviews Clinical Oncology 2010; 7:521-532.
  • High incidence of Pneumocytis Jiroveci Pneumonia (PCP) in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine & prednisone (R-CHOP-14). Leukemia & Lymphoma 2010; 51:797-801.
  • Intra-atrial Thrombosis Complicating Myocardial Relapse of Leukemia. European Journal of Haematology 2010; 84:187.
  • Extra-Nasal NK/T Cell Lymphoma Masquerading as Renal Infarction. Leukemia & Lymphoma 2010;51:1139-41.
  • The Paradox of 20q11.21 Amplification in a Subset of Cases of Myeloid Malignancy with Chromosome 20 Deletion. Genes Chromosomes Cancer. 2010 Nov;49(11):998-1013.
  • Mechanism of Action of Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Leukemia. 2010;24(1):22-32.
  • Testing the NKT Cell Hypothesis in Lenalidomide-Treated Myelodysplastic Syndrome Patients. Leukemia 2010; 24(3):592-600